Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, William J. Sandborn et al.|The Lancet|2017Cited by 198
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, Paul Hellstern et al.|Journal of Crohn s and Colitis|2021Cited by 34
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate RespondersSilvio Danese, Stefan Schreiber, Séverine Vermeire et al.|Gastroenterology|2016Cited by 7
DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT IIWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Journal of Crohn s and Colitis|2019Cited by 5